Widespread Use of Measurable Residual Disease in Acute Myeloid Leukemia Practice

被引：0
|
作者：
Epstein-Peterson, Zachary D.
Devlin, Sean M.
Stein, Eytan M.
Estey, Elihu H.
Tallman, Martin S.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5103
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia
    Gaut, Daria
    Oliai, Caspian
    Boiarsky, Jonathan
    Zhang, Shiliang
    Salhotra, Amandeep
    Azenkot, Tali
    Kennedy, Vanessa E.
    Khanna, Vishesh
    Olmedo Gutierrez, Karla
    Shukla, Navika
    Moskoff, Benjamin
    Park, Gabriel
    Afkhami, Michelle
    Patel, Anand
    Jeyakumar, Deepa
    Mannis, Gabriel
    Logan, Aaron C.
    Jonas, Brian A.
    Schiller, Gary
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 69 - 77
  • [22] Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia
    Palmieri, Raffaele
    Buccisano, Francesco
    Maurillo, Luca
    Del Principe, Maria, I
    Paterno, Giovangiacinto
    Venditti, Adriano
    Martinelli, Giovanni
    Cerchione, Claudio
    MINERVA MEDICA, 2020, 111 (05) : 386 - 394
  • [23] Measurable residual disease in multiple myeloma and in acute myeloid leukemia, an evolving topic
    Castelli, Germana
    Pelosi, Elvira
    Testa, Ugo
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2021, 57 (04): : 300 - 313
  • [24] Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia
    Roehnert, M. A.
    Kramer, M.
    Schadt, J.
    Ensel, P.
    Thiede, C.
    Krause, S.
    Buecklein, V
    Hoffmann, J.
    Jaramillo, S.
    Schlenk, R.
    Roellig, C.
    Bornhaeuser, M.
    McCarthy, N.
    Freeman, S.
    Oelschlaegel, U.
    von Bonin, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 278 - 278
  • [25] Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia
    Percival, Mary-Elizabeth M.
    Estey, Elihu H.
    CANCER, 2019, 125 (18) : 3121 - 3130
  • [26] Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
    Paterno, Giovangiacinto
    Del Principe, Maria Ilaria
    Venditti, Adriano
    CURRENT OPINION IN HEMATOLOGY, 2020, 27 (02) : 81 - 87
  • [27] Tracking Measurable Residual Disease in Acute Myeloid Leukemia with Error Corrected Sequencing
    D'Angelo, J.
    Huang, Y.
    Kebede, Y.
    Miick, S.
    Salva, N.
    Troung, C.
    Turner, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S38 - S38
  • [28] Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
    Walter, Roland B.
    Ofran, Yishai
    Wierzbowska, Agnieszka
    Ravandi, Farhad
    Hourigan, Christopher S.
    Ngai, Lok Lam
    Venditti, Adriano
    Buccisano, Francesco
    Ossenkoppele, Gert J.
    Roboz, Gail J.
    LEUKEMIA, 2021, 35 (06) : 1529 - 1538
  • [29] Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
    Tanja Božić
    Chao-Chung Kuo
    Jan Hapala
    Julia Franzen
    Monika Eipel
    Uwe Platzbecker
    Martin Kirschner
    Fabian Beier
    Edgar Jost
    Christian Thiede
    Wolfgang Wagner
    Leukemia, 2022, 36 : 80 - 89
  • [30] CLINICAL IMPACT OF MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA (AML)
    Venditti, A.
    Buzzatti, E.
    Guarnera, L.
    Bonanni, F.
    Moretti, F.
    Pascale, M. R.
    Mallegni, F.
    Palmieri, R.
    Paterno, G.
    Del Principe, M. I.
    Maurillo, L.
    Voso, M. T.
    Buccisano, F.
    HAEMATOLOGICA, 2021, 106 (10) : 202 - 205
12345